NEW YORK, Nov. 29, 2017 /PRNewswire/ -- CEFALY Technology announces today the release of two new U.S. Food and Drug
The CefalyŽ ACUTE can help rescue a migraine already in progress. The CefalyŽ DUAL is a device that combines the newly approved ACUTE treatment with its prophylactic predecessor, the CefalyŽ 2; now more appropriately renamed CefalyŽ PREVENT.
"We are excited that we can now offer migraine patients several drug-free options in their migraine care," said Dr. Pierre Rigaux, the chief executive officer of CEFALY Technology, and a member of the team that invented the device. "We have developed a way for migraine patients to stop a migraine and prevent a migraine without medication and with next-to-no side effects."
The new FDA-approval follows several clinical trials that demonstrated that one hour of e-TNS with the CefalyŽ ACUTE can relieve or stop the migraine headache. Results from the acute treatment of migraine with external trigeminal nerve stimulation double-blind randomized placebo control trial were presented at a recent meeting of the International Headache Society. The findings showed that on average, the CefalyŽ treatment reduced migraine pain by 65%. In addition, 32% of patients were pain free within an hour.
Proprietary CefalyŽ technology has been adapted to efficiently and safely address the different phases of migraines. There are now three treatment options: CefalyŽ PREVENT, a prophylaxis treatment; CefalyŽ ACUTE, a rescue treatment, and CefalyŽ DUAL, a device that combines both prevent and acute technologies.
Despite these differences, the devices are administered in the same way: a device is placed on the forehead via a magnetic connection to a self-adhesive electrode, which then sends precise micro-impulses through the skin to the upper branches of the trigeminal nerve to either relieve headache pain during a migraine attack or to prevent a future migraine attack. All CefalyŽ devices are available to adults by prescription-only.
About CEFALY TechnologyCEFALY Technology is a Belgium-based company, with US offices based in Wilton, Connecticut, specializing in electronics for medical applications. It has developed external cranial stimulation technology for applications in the field of neurology; in particular for treating migraines. For more information, visit http://www.cefaly.us. Find Cefaly on Twitter: @Cefaly and on Facebook: http://www.facebook.com/CefalyEN.
Media Contact: Maria Coder[email protected]
View original content:http://www.prnewswire.com/news-releases/fda-approved-cefaly-device-to-stop-migraines-now-available-300563323.html
SOURCE CEFALY Technology
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All